Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MedImmune takes on managed care

MedImmune takes on managed care

Products to prevent disease sound perfect for the managed care environment - until it comes time for someone to pay for them.

MedImmune Inc.'s RespiGam specialty immune globulin to prevent respiratory syncytial virus in high-risk infants was approved last January, and the company has had all year to prepare for a full launch during this fall's RSV season. The company is tackling the managed care problem directly by working to enlist managed care providers on its side. With 60 million patients enrolled in HMOs this year, a number expected to rise

Read the full 964 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE